Phathom Pharmaceuticals

company

About

Phathom Pharmaceuticals is a biopharmaceutical company.

  • 51 - 100

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$40M
Industries
Biotechnology,Pharmaceutical
Founded date
Jan 1, 2018
Number Of Employee
51 - 100
Operating Status
Active

Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.

Phathom has assembled a leading team of seasoned gastrointestinal and pharmaceutical industry experts with proven experience developing and commercializing highly innovative therapies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$240M
Phathom Pharmaceuticals has raised a total of $240M in funding over 2 rounds. Their latest funding was raised on Nov 1, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 1, 2022 Post-IPO Debt $40M 2 Detail
Sep 20, 2021 Post-IPO Debt $200M 1 Hercules Capital Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Phathom Pharmaceuticals is funded by 2 investors. Hercules Capital and Sagard Healthcare Royalty Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Post-IPO Debt
Sagard Healthcare Royalty Partners Post-IPO Debt